NasdaqCM - Delayed Quote USD

RedHill Biopharma Ltd. (RDHL)

Get top stock picks

0.7244 +0.0116 (+1.63%)

At close: September 4 at 4:00:00 PM EDT

0.7020 -0.0224 (-3.09%)

After hours: September 4 at 7:53:38 PM EDT

Get top stock picks

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

CNW Group 6d ago

RDHL
+1.63%
APTX.TO
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

PR Newswire 2mo ago

RDHL
+1.63%
RedHill Biopharma Announces Up To $19.4 Million Private Placement

PR Newswire 2mo ago

RDHL
+1.63%
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

PR Newswire 3mo ago

RDHL
+1.63%
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

PR Newswire 5d ago

RDHL
+1.63%
HYL
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

GlobeNewswire 5d ago

RDHL
+1.63%
Redhill Biopharma Stock Doubles In One Session — Here's Why

Benzinga 5d ago

RDHL
+1.63%
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

PR Newswire 6d ago

RDHL
+1.63%
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

GlobeNewswire 5d ago

ANTX

RDHL
+1.63%
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

PR Newswire 1mo ago

ABVX

MRK

RDHL
+1.63%
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

PR Newswire 1mo ago

RDHL
+1.63%
GILD
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

PR Newswire 4mo ago

RDHL
+1.63%
CPIX

Yahoo Finance

U.S. markets closed

RedHill Biopharma Ltd. (RDHL)

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

Redhill Biopharma Stock Doubles In One Session — Here's Why

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026